Studies a nasal spray medicine, zavegepant, in children with migraine
Tests zavegepant nasal spray for safety in children aged 6 to 11 with migraine.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Key facts
- Where
- Cincinnati, Dallas, Hinesville, Minneapolis, Omaha, Philadelphia, Port Jefferson Station, Salt Lake City, Statesville, Tulsa, Washington D.C., and Winston-Salem, United StatesSee the 14 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 11 years old?
Source: NCT06995729, who can take part
Where in United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesTaking people
- Cedar Health ResearchDallas, United StatesNo longer taking part
- Coastal Heritage Clinical ResearchHinesville, United StatesTaking people
- Clinical Research InstituteMinneapolis, United StatesTaking people
- Children'S Hospital & Medical CenterOmaha, United StatesTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesTaking people
- True North NeurologyPort Jefferson Station, United StatesTaking people
- Granger Medical Holladay - Holladay ClinicSalt Lake City, United StatesNo longer taking part
- Wasatch Clinical Research, LLCSalt Lake City, United StatesNo longer taking part
- Accellacare - PiedmontStatesville, United StatesTaking people
- Accellacare of Piedmont HealthCareStatesville, United StatesTaking people
- Central States ResearchTulsa, United StatesTaking people
- Velocity Clinical Research, Washington DCWashington D.C., United StatesTaking people
- Accellacare US Inc.Winston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06995729
- Record updated
- 28 September 2026
- Original description
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it.Read full original descriptionShow less
A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it.
This study is seeking participants who:
* Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms
All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs.
The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine.
Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.
Inclusion: Participants aged 6 years to less than 12 years; Documented medical history of migraine with or without aura for at least 6 months before the Screening Visit; Weight >15 kg at the Screening Visit.
Exclusion: Continuous migraine (defined as an unrelenting headache) within 1 month prior to Screening Visit; Evidence or history of clinically significant disease; Atypical migraine types, complications of a migraine, or a confounding and clinically significant pain syndrome; Conditions that may affect the administration or absorption of the nasal product; Any psychiatric condition that is uncontrolled and/or untreated, including:; Clinically significant depression (Promis Parent Proxy SF 2.0 Depressive Scale T score ≥70); Suicidal ideation and behaviour (C-SSRS: any "yes" to items 2 to 5 or any "yes" to suicide behaviours); Serum Total bilirubin >1.5 × ULN (Upper Limit of Normal), AST (Aspartate Transferase) or ALT (Alanine Transaminase) >2 × ULN; Abnormal ECG (Electrocardiogram) at screening visit.